Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in the rat embryonic spinal cells

Khoshdel, Zahra; Takhshid, Mohammad Ali; Owji, Ali Akbar

doi:10.1016/j.npep.2015.12.011

Cited by 12 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies show that administration of amylin in mice reduces pain-related behaviours, such as reducing writhing and tail flicks, and increases the latency in the hot plate test. This reduction in pain behaviour with amylin was consistently attenuated when amylin antagonists, such as AC187 and rat Amy 8-37 , were administered (Khoshdel et al, 2019(Khoshdel et al, , 2016Sibilia et al, 2000;X. Huang et al, 2010).…”

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 95%

“…Huang et al, 2010). Co-administration of amylin with morphine resulted in reduced morphine tolerance, and amylin alone demonstrated an analgesic action comparable with morphine in tail flick tests (Khoshdel et al, 2016(Khoshdel et al, , 2019. Interestingly, intrathecal, but not intraperitoneal, injection of amylin was able to reduce the number of formalin-induced flinches in pain Phases I and II.…”

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 95%

“…Interestingly, intrathecal, but not intraperitoneal, injection of amylin was able to reduce the number of formalin-induced flinches in pain Phases I and II. This suggests that central amylin administration is required to attenuate acute neurogenic pain mediated by nociceptive C fibres in Phase I and inflammatory pain mediated by the peripheral tissues and the spinal cord in Phase II (Khoshdel et al, 2016;Potes et al, 2016). Additionally, intra- Phase II (Potes et al, 2016).…”

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 99%

See 2 more Smart Citations

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Rees

Hendrikse

Hay

et al. 2021

British J Pharmacology

View full text Add to dashboard Cite

The CGRP system has emerged as a key pharmacological target for the treatment of migraine. However, some individuals who suffer from migraine have low or no response to anti-CGRP or other treatments, suggesting the need for additional clinical targets. CGRP belongs to the calcitonin family of peptides, which includes calcitonin, amylin, adrenomedullin and adrenomedullin 2. These peptides display a range of pro-nociceptive and anti-nociceptive actions, in primary headache conditions such as migraine. Calcitonin family peptides also show expression at sites relevant to migraine and pain. This suggests that calcitonin family peptides and their receptors, beyond CGRP, may be therapeutically useful in the treatment of migraine and other pain disorders. This review considers the localisation of the calcitonin family in peripheral pain pathways and discusses how they may contribute to migraine and pain.

show abstract

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 95%

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 95%

Section: Overview and Contribution Of Amylin To Migraine And Painmentioning

confidence: 99%

See 1 more Smart Citation

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Rees

Hendrikse

Hay

et al. 2021

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…As noted, both CGRP and amylin are reported to have effects relating to pain, though there are still limited data and it is unclear how much overlap there is because the peptides are not usually tested in the same study . Amylin reduces pain in formalin and acetic acid tests, it has analgesic effects in models of visceral pain when administered peripherally, and antinociceptive effects are linked to reduced spinal c‐fos expression; on the other hand, no effects were evident in a tail‐immersion test when given centrally . However, amylin knockout mice have reduced nociception .…”

Section: Amylin: Pain and Other Actionsmentioning

confidence: 99%

“…56 Amylin reduces pain in formalin and acetic acid tests, it has analgesic effects in models of visceral pain when administered peripherally, and antinociceptive effects are linked to reduced spinal c-fos expression; on the other hand, no effects were evident in a tail-immersion test when given centrally. [57][58][59][60][61] However, amylin knockout mice have reduced nociception. 62 In all cases, there is no clear evidence that a particular amylin receptor is involved, given the complexity in the amylin receptor system.…”

Section: Amylin: Pain and Other Actionsmentioning

confidence: 99%

Amylin

Hay

2017

Headache

View full text Add to dashboard Cite

Amylin is a 37 amino acid peptide hormone that is closely related to calcitonin gene-related peptide (CGRP). Amylin and CGRP share a receptor and are reported to have several similar biological actions. Given the important role of CGRP in migraine and intense efforts to develop drugs against this target, it is important to consider potential areas of overlap between the amylin and CGRP systems. This short review provides a brief introduction to amylin biology, the use of an amylin analog to treat diabetes, and consideration of whether amylin could have any role in headache disorders. Finally, this review informs readers about the AMY 1 (amylin subtype 1) receptor, which is a dual receptor for amylin and CGRP and potentially plays a role in the bioactivity of both of these peptides.

show abstract

Amylin Analog Pramlintide Induces Migraine‐like Attacks in Patients

Ghanizada

Al‐Karagholi

Walker

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

Objective Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood, and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene‐related peptide (CGRP). Methods Thirty‐six migraine without aura patients were enrolled in a randomized, double‐blind, 2‐way, crossover, positive‐controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days. Furthermore, translational studies in cells and mouse models, and rat, mouse and human tissue samples were conducted. Results Thirty patients (88%) developed headache after pramlintide infusion, compared to 33 (97%) after CGRP (p = 0.375). Fourteen patients (41%) developed migraine‐like attacks after pramlintide infusion, compared to 19 patients (56%) after CGRP (p = 0.180). The pramlintide‐induced migraine‐like attacks had similar clinical characteristics to those induced by CGRP. There were differences between treatments in vascular parameters. Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide‐provoked effects, rather than the canonical CGRP receptor. Supporting this, preclinical experiments investigating symptoms associated with migraine showed that amylin treatment, like CGRP, caused cutaneous hypersensitivity and light aversion in mice. Interpretation Our findings propose amylin receptor agonism as a novel contributor to migraine pathogenesis. Greater therapeutic gains could therefore be made for migraine patients through dual amylin and CGRP receptor antagonism, rather than selectively targeting the canonical CGRP receptor. ANN NEUROL 2021;89:1157–1171

show abstract

Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in the rat embryonic spinal cells

Cited by 12 publications

References 38 publications

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Amylin

Amylin Analog Pramlintide Induces Migraine‐like Attacks in Patients

Contact Info

Product

Resources

About